跳至主要内容
临床试验/NCT02814240
NCT02814240已完成不适用

Hepatic Steatosis and Pituitary Gland Failure, Evaluation by NMR Imaging

Centre Hospitalier Universitaire Dijon2 个研究点 分布在 1 个国家目标入组 21 人开始时间: 2015年3月16日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
21
试验地点
2
主要终点
Measurement of liver fat mass by Magnetic Resonance Imaging (MRI)

研究概览

简要总结

The investigator put forward the hypothesis that liver fat mass in patients with pituitary gland failure is greater than that in a control population. Failure of the anterior pituitary and more particularly impaired production of growth hormone (GH) could be the principal mechanism responsible for increased liver fat mass in these patients.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients who have provided consent
  • Patients over 18 years
  • Patients with pituitary disease (Pituitary adenoma, anterior pituitary failure, craniopharyngioma, empty sella syndrome, hypophysitis, infiltration of the stalk) requiring Magnetic Resonance Imaging (MRI) of the pituitary.

排除标准

  • Persons without national health insurance
  • Pacemaker (Contra-Indication for MRI)
  • Alcohol consumption greater than 4 glasses a day
  • Any treatment able to increase liver fat content (glitazones, systemic corticoids, immunosuppressants) are forbidden
  • Presence of metallic implants (Contra-Indication for MRI)
  • Claustrophobia
  • Adult under guardianship
  • Pregnant or breast-feeding women
  • Patients with a liver disease other than non-alcoholic steatosis

研究组 & 干预措施

Pituitary gland failure

Experimental

干预措施: fibroscan (Other)

Pituitary gland failure

Experimental

干预措施: NMR (Other)

Pituitary gland failure

Experimental

干预措施: Blood samples (Biological)

结局指标

主要结局

Measurement of liver fat mass by Magnetic Resonance Imaging (MRI)

时间窗: Measured at Day 0

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验